Table 5.
Anti-vascular endothelial growth factor (Anti-VEGF) clinical trials.
| Study Name | Drug | Control | Treatment | Follow up | Change in ETDRS | |
|---|---|---|---|---|---|---|
| Treatment 1 | Control 2 | |||||
| MARINA [218] | Ranibizumab | Sham injections q 4 weeks | Ranibizumab 0·5 mg q 4 weeks | 1 year | +7.2 | –10.4 |
| ANCHOR [219] | Ranibizumab | Sham injection q 4 weeks plus PDT | Ranibizumab 0·5 mg q 4 weeks+ sham PDT | 1 year | +11.3 | –9.5 |
| HARBOR [220] | Ranibizumab | Ranibizumab 0·5 q 4 weeks | Ranibizumab 0·5 mg q 4 weeks × 3 months then as required | 2 years | +7.9 | +9.1 |
| TREX [221] | Ranibizumab | Ranibizumab 0·5 q 4 weeks | Ranibizumab 0·5 mg q 4 weeks × 3 months until disease inactive then extension per protocol | 1 year | +10.5 | +9.2 |
| FOCUS [222] | Ranibizumab | Sham injections+PDT | Ranibizumab+PDT 0.5 mg q 4 weeks, PDT = day one + quarterly if needed | 2 years | 4.6 | −7.8 |
| BRAMD [223] | Bevacizumab | Ranibizumab 0·5 mg q 4 weeks | Bevacizumab 1·25 mg q 4 weeks | 1 year | +5.1 | +6.4 |
| LUCAS [224] | Bevacizumab | Ranibizumab 0·5 mg q 4 weeks until nvAMD is inactive, then extension by 2 weeks (maximum of 12 weeks) | Bevacizumab 1·25 mg q 4 weeks until nvAMD is inactive, then extension by 2 weeks (maximum of 12 weeks) | 1 year | +7.9 | +8.2 |
| CATT [225] | Bevacizumab | Ranibizumab 0·5 mg q 4 weeks | Bevacizumab 1·25 mg q 4 weeks | 1 year | +7.8 | +8.8 |
| GEFAL [226] | Bevacizumab | Ranibizumab 0·5 mg q 4 weeks × 3 months, then as needed | Bevacizumab 0·5 mg q 4 weeks × 3 months, then as needed | 1 year | +4.8 | +2.9 |
| IVAN [227] | Bevacizumab | Ranibizumab 0·5 mg q 4 weeks | Bevacizumab 1·25 mg q 4 weeks | 2 yearss | +4.1 | +4.9 |
| VIEW 1 [228] | Aflibercept | Ranibizumab 0·5 mg q 4 weeks | Aflibercept 2 mg every 2 months | 1 year | +7.9 | +8.1 |
| VIEW 2 [228] | Aflibercept | Ranibizumab 0·5 mg q 4 weeks | Aflibercept 2 mg every 2 months | 1 year | +8.9 | +9.4 |
| HAWK [229] | Brolucizumab | Aflibercept 2 mg q 8 weeks | Brolucizumab 3 mg q 12 weeks Or Brolucizumab 6 mg q12 weeks |
96 weeks | +5.6 +5.9 |
+5.3 |
| HARRIER [229] | Brolucizumab | Aflibercept 2 mg q 8 weeks | Brolucizumab 6 mg q12 weeks | 96 weeks | +6.1 | +6.6 |
| AURORA [230] | Conbercept | Conbercept 0·5 mg q 4 weeks × 3 months, then monthly or as required | Conbercept 2 mg q 4 weeks × 3 months, then monthly or as required | 1 year | +15.4 | +9.3 |
| PHOENIX [231] | Conbercept | Sham injections q 4 weeks × 3 months then conbercept 0.5 mg q 4 weeks × 3 months | Conbercept 0.5 mg q 4 weeks × 3 months, then quarterly | 1 year | +9.98 | +8.81 |
| STAIRWAY [232] | Farcizumab | 0.5 mg ranibizumab q 4 weeks × 52 weeks | Farcizumab 6 mg q 16 weeks | 52 weeks | +11.4 | +9.6 |
| Or | ||||||
| Farcizumab 6 mg q 12 weeks | +10.1 | |||||
1 = Letters gained with treatment; 2 = Letters gained/lost from baseline control.